These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23318930)

  • 1. Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration.
    Caesar M; Zach S; Carlson CB; Brockmann K; Gasser T; Gillardon F
    Neurobiol Dis; 2013 Jun; 54():280-8. PubMed ID: 23318930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    Gillardon F
    J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro.
    Gillardon F
    Neuroscience; 2009 Oct; 163(2):533-9. PubMed ID: 19559761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
    Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
    Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation.
    Law BM; Spain VA; Leinster VH; Chia R; Beilina A; Cho HJ; Taymans JM; Urban MK; Sancho RM; Blanca Ramírez M; Biskup S; Baekelandt V; Cai H; Cookson MR; Berwick DC; Harvey K
    J Biol Chem; 2014 Jan; 289(2):895-908. PubMed ID: 24275654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
    Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
    Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate.
    Krumova P; Reyniers L; Meyer M; Lobbestael E; Stauffer D; Gerrits B; Muller L; Hoving S; Kaupmann K; Voshol J; Fabbro D; Bauer A; Rovelli G; Taymans JM; Bouwmeester T; Baekelandt V
    FASEB J; 2015 Jul; 29(7):2980-92. PubMed ID: 25854701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
    Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
    PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
    Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
    Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
    Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
    PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
    Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E
    J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
    Luerman GC; Nguyen C; Samaroo H; Loos P; Xi H; Hurtado-Lorenzo A; Needle E; Stephen Noell G; Galatsis P; Dunlop J; Geoghegan KF; Hirst WD
    J Neurochem; 2014 Feb; 128(4):561-76. PubMed ID: 24117733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in actin dynamics and F-actin structure both in synaptoneurosomes of LRRK2(R1441G) mutant mice and in primary human fibroblasts of LRRK2(G2019S) mutation carriers.
    Caesar M; Felk S; Aasly JO; Gillardon F
    Neuroscience; 2015 Jan; 284():311-324. PubMed ID: 25301747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.
    Schwab AJ; Ebert AD
    Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.
    Huang L; Shimoji M; Wang J; Shah S; Kamila S; Biehl ER; Lim S; Chang A; Maguire-Zeiss KA; Su X; Federoff HJ
    Neurotherapeutics; 2013 Oct; 10(4):840-51. PubMed ID: 23963789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
    Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
    J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
    Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
    Neurochem Res; 2016 Oct; 41(10):2675-2692. PubMed ID: 27394417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.
    Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F
    Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.